1931 (1931) Fair Value & Analysis

Healthcare · Market cap HK$1.0B

1 1931 1931 · HK

PriceHK$0.6300

Fair ValueHK$0.6400

Upside+1.6%

Quality24/100

Watch 1931 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$0.4200 – HK$0.8300

Fair value as of: Jul 2, 2026

From 16 valuation models · updated today

Share price −12.5% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.5800 – HK$11.23 · fair‑value band HK$0.4200 – HK$0.8300 · the HK$0.6300 price screens below the HK$0.6400 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1931 (1931) currently trades at HK$0.6300, while our model-based Fair Value estimate is HK$0.6400 — implying the stock looks roughly 1.6% undervalued today. We read business quality at 24/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 1931 generated revenue of HK$2.8B at a net margin of 1.2%. Revenue declined 14.3% year over year. It earns a return on equity of 1.1%. Net debt stands at HK$1.4B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$2.8B

Revenue growth (YoY) -14.3%

Net margin 1.2%

Return on equity 1.1%

Free cash flow −HK$1.0B FY2025

P/E ratio 31.5

More key figures

Operating margin 4.3%

EPS (TTM) HK$0.0200

EPS growth (YoY) -74.0%

Net debt HK$1.4B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1931 reported revenue of HK$2.8B in FY2025 versus HK$2.7B in FY2021, a compound +0.8%/yr. Reported net income was HK$34.9M in FY2025, compounding −33.1%/yr from FY2021.

Revenue +0.8%/yr

FY21 HK$2.7B

FY22 HK$2.7B

FY23 HK$3.1B

FY24 HK$3.2B

FY25 HK$2.8B

Net income −33.1%/yr

FY21 HK$175M

FY22 HK$210M

FY23 HK$238M

FY24 HK$260M

FY25 HK$34.9M

Is 1931 fairly valued? → Check now

Similar stocks

6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
McKesson Corporation M1CK34	R$1,022	R$1,243	+22%
Cencora, Inc C1CO34	R$709.32	R$400.70	-44%
Cardinal Health, Inc CAH	$216.30	$110.75	-49%
Sigma Healthcare Limited SIGGF	$2.35	$0.7800	-67%
SIG SIG	A$2.76	A$0.3300	-88%
Shanghai Pharmaceuticals Holding 601607	¥15.96	¥56.73	+255%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1931 (1931) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.6400 versus a price of HK$0.6300 — about +2% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 1931?

Our model-based fair value for 1931 is HK$0.6400 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.6300.

What is the quality score of 1931?

1931 has a Quality Score of 24/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1931 (1931)?

1931 reported trailing-twelve-month revenue of about HK$2.8B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1931?

The net profit margin of 1931 is about 1.2%, meaning it keeps roughly 1.2% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.